2019 AAPM Annual Meeting
Back to session list

Session Title: Cutting-edge Brachytherapy
Question 1: What is the approximate average photon energy emitted by a 169Yb source?
Reference:Reynoso FJ, Munro JJ, Cho SH, “Technical Note: Monte Carlo calculations of the AAPM TG-43 brachytherapy dosimetry parameters for a new titanium-encapsulated Yb-169 source,” Journal of Applied Clinical Medical Physics 18(4), 193-199 (2017).
Choice A:380 keV
Choice B:25 keV
Choice C:93 keV
Choice D:61 keV
Question 2: In a center participating in EMBRACE II, what percentage of patients must receive combined intracavitary and interstitial brachytherapy?
Reference:Pötter et al, The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies, Clinical and Translational Radiation Oncology 9, 48-60 (2018).
Choice A:5%
Choice B:10%
Choice C:20%
Choice D:50%
Question 3: Patients receiving single-fraction high-dose-rate brachytherapy monotherapy for prostate cancer have found results at 5+ years to be the following relative to conventionally-fractionated high-dose-rate brachytherapy:
Reference:Siddiqui ZA, Gustafson GS, Ye H, Martinez AA, Mitchell B, Sebastian E, Limbacher A, Krauss DJ, “Five-year outcomes of a single-institution prospective trial of 19-Gy single-fraction high-dose-rate brachytherapy for low- and intermediate-risk prostate cancer,” International Journal of Radiation Oncology*Biology*Physics, In Press as of Feb. 13, 2019.
Choice A:Low toxicity, low biochemical control
Choice B:Low toxicity, high biochemical control
Choice C:High toxicity, low biochemical control
Choice D:High toxicity, high biochemical control
Question 4: Which of the following description(s) is/are correct about prostate volume in HDR brachytherapy?
Reference:Yang X, Rossi PJ, Jani AB, Mao H, Zhou Z, Curran WJ, Liu T. Improved prostate delineation in prostate HDR brachytherapy with TRUS-CT deformable registration technology: A pilot study with MRI validation. J Appl Clin Med Phys. 2017; 18(1):202-10. doi: 10.1002/acm2.12040. PubMed PMID: 28291925; PMCID: PMC5689894.
Choice A:Planning CT overestimates prostate volume compared with MRI and ultrasound
Choice B:Diagnostic MRI captured two weeks before HDR brachytherapy provides the most authentic prostate volume for brachytherapy planning
Choice C:3D Intraoperative ultrasound images provide the most authentic prostate volume for brachytherapy planning
Choice D:a and c
Question 5: Which of the following are correct about image-guided HDR prostate brachytherapy?
Reference:Wang T, Press RH, Giles M, Jani AB, Rossi P, Lei Y, Curran W, Patel P, Liu T and Yang X. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy. Br J Radiol 2019; 92: 20190089
Choice A:The dominant intraprostatic lesion (DIL) is the most common sites of recurrence after radiation therapy
Choice B:Multiparametric MRI has the same performance to define DILs compared with CT
Choice C:Using visualized DILs to guide HDR catheter placement may improve the DIL dose boost level and coverage without violating organ-at-risk constraints
Choice D:a and c
Question 6: What is the effective working volume of current electromagnetic tracking technology:
Reference:Boutaleb, Samir, Emmanuel Racine, Olivier Filion, Antonio Bonillas, Gilion Hauvast, Dirk Binnekamp, and Luc Beaulieu. “Performance and Suitability Assessment of a Real-Time 3D Electromagnetic Needle Tracking System for Interstitial Brachytherapy.” J Contemp Brachytherapy 7 (2015) 280–89.
Choice A:10x10x10 mm3
Choice B:10x10x10 cm3
Choice C:50x50x50 cm
Choice D:2x2x2 m3
Question 7: What is the typical accuracy expected from the electromagnetic tracking technology when used optimally?
Reference:Franz, Alfred M, Tamas Haidegger, Wolfgang Birkfellner, Kevin Cleary, Terry M Peters, and Lena Maier-Hein. “Electromagnetic Tracking in Medicine--a Review of Technology, Validation, and Applications..” IEEE Trans Med Imaging 33 (2014) 1702–25.
Choice A:Perfect
Choice B:Around 0.5 mm
Choice C:Between 1-3 mm
Choice D:Around 5 mm
Question 8: What kind of action can electromagnetic tracking perform?
Reference:Damato, Antonio L, Akila N Viswanathan, Sarah M Don, Jorgen L Hansen, and Robert A Cormack. “A System to Use Electromagnetic Tracking for the Quality Assurance of Brachytherapy Catheter Digitization..” Medical Physics 41 (2014) 101702. Poulin, E, E Racine, D Binnekamp, and L. Beaulieu. “Fast, Automatic, and Accurate Catheter Reconstruction in HDR Brachytherapy Using an Electromagnetic 3D Tracking System.” Medical Physics 42 (2015) 1227–32.
Choice A:Tracking of needle and catheter insertion
Choice B:Catheter and applicator reconstruction
Choice C:Detection of catheter shifts
Choice D:All of the above
Question 9: What of the following statements is FALSE about medical events (MEs) in HDR brachytherapy?
Reference:Thomadsen et al., A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy: Executive summary, Practical Radiation Oncology (2014) 4, 65–70.
Choice A:Have been due to a lack of guidance documents
Choice B:Have been due to human failures in performance of tasks
Choice C:Have been due to mechanical failures
Choice D:Have been due to errors during the treatment planning process
Question 10: Which of the following statements is TRUE about scripting?
Reference:Cai et al., Standardization and automation of quality assurance for high-dose-rate brachytherapy planning with application programming interface, Brachytherapy (2019), 18 (1), 108-114.e1.
Choice A:Scripting is programming via a vendor-supported interface to access plan information from the treatment planning system
Choice B:Scripting is only available in the ES-API environment
Choice C:Scripting tools for brachytherapy have been studied and developed by many groups
Choice D:Scripting has been used to successfully automate the performance of all manual checks for plan QA
Back to session list